The Korean Journal of Pain

  • 제33권2호
  • /
  • Pages.108-120
  • /
  • 2020
  • /
  • 2005-9159(pISSN)
  • /
  • 2093-0569(eISSN)
대한통증학회 (The Korean Pain Society)
권호 표지
DOI QR코드

DOI QR Code

All about pain pharmacology: what pain physicians should know

  • Kim, Kyung-Hoon (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University) ;
  • Seo, Hyo-Jung (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University) ;
  • Abdi, Salahadin (Department of Pain Medicine, The University of Texas MD Anderson Cancer Center) ;
  • Huh, Billy (Department of Pain Medicine, The University of Texas MD Anderson Cancer Center)
  • 투고 : 2020.02.08
  • 심사 : 2020.03.13
  • 발행 : 2020.04.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

From the perspective of the definition of pain, pain can be divided into emotional and sensory components, which originate from potential and actual tissue damage, respectively. The pharmacologic treatment of the emotional pain component includes antianxiety drugs, antidepressants, and antipsychotics. The anti-anxiety drugs have anti-anxious, sedative, and somnolent effects. The antipsychotics are effective in patients with positive symptoms of psychosis. On the other hand, the sensory pain component can be divided into nociceptive and neuropathic pain. Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are usually applied for somatic and visceral nociceptive pain, respectively; anticonvulsants and antidepressants are administered for the treatment of neuropathic pain with positive and negative symptoms, respectively. The NSAIDs, which inhibit the cyclo-oxygenase pathway, exhibit anti-inflammatory, antipyretic, and analgesic effects; however, they have a therapeutic ceiling. The adverse reactions (ADRs) of the NSAIDs include gastrointestinal problems, generalized edema, and increased bleeding tendency. The opioids, which bind to the opioid receptors, present an analgesic effect only, without anti-inflammatory, antipyretic, or ceiling effects. The ADRs of the opioids start from itching and nausea/vomiting to cardiovascular and respiratory depression, as well as constipation. The anticonvulsants include carbamazepine, related to sodium channel blockade, and gabapentin and pregabalin, related to calcium blockade. The antidepressants show their analgesic actions mainly through inhibiting the reuptake of serotonin or norepinephrine. Most drugs, except NSAIDs, need an updose titration period. The principle of polypharmacy for analgesia in case of mixed components of pain is increasing therapeutic effects while reducing ADRs, based on the origin of the pain.

키워드

참고문헌

  1. Merskey H, Albe Fessard D, Bonica JJ, Carmon A, Dubner R, Kerr FWL, et al. Pain terms: a list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy. Pain 1979; 6: 249-52.
  2. Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain 2003; 102: 1-8. https://doi.org/10.1016/s0304-3959(03)00006-x
  3. Baron R, Maier C, Attal N, Binder A, Bouhassira D, Cruccu G, et al. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain 2017; 158: 261-72. https://doi.org/10.1097/j.pain.0000000000000753
  4. Attal N, Fermanian C, Fermanian J, Lanteri-Minet M, Alchaar H, Bouhassira D. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? Pain 2008; 138: 343-53. https://doi.org/10.1016/j.pain.2008.01.006
  5. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, et al. Development and validation of the neuropathic pain symptom inventory. Pain 2004; 108: 248-57. https://doi.org/10.1016/j.pain.2003.12.024
  6. Loeser JD, Treede RD. The Kyoto protocol of IASP basic pain terminology. Pain 2008; 137: 473-7. https://doi.org/10.1016/j.pain.2008.04.025
  7. Kallakuri S, Singh A, Chen C, Cavanaugh JM. Demonstration of substance P, calcitonin gene-related peptide, and protein gene product 9.5 containing nerve fibers in human cervical facet joint capsules. Spine (Phila Pa 1976) 2004; 29: 1182-6. https://doi.org/10.1097/00007632-200406010-00005
  8. Park SC, Kim KH. Effect of adding cervical facet joint injections in a multimodal treatment program for long-standing cervical myofascial pain syndrome with referral pain patterns of cervical facet joint syndrome. J Anesth 2012; 26: 738-45. https://doi.org/10.1007/s00540-012-1404-8
  9. Kim TK, Kim KH, Kim CH, Shin SW, Kwon JY, Kim HK, et al. Percutaneous vertebroplasty and facet joint block. J Korean Med Sci 2005; 20: 1023-8. https://doi.org/10.3346/jkms.2005.20.6.1023
  10. Kim KH, Choi SH, Kim TK, Shin SW, Kim CH, Kim JI. Cervical facet joint injections in the neck and shoulder pain. J Korean Med Sci 2005; 20: 659-62. https://doi.org/10.3346/jkms.2005.20.4.659
  11. Demondion X, Vidal C, Glaude E, Subocz L, Francke JP, Cotten A. The posterior lumbar ramus: CT-anatomic correlation and propositions of new sites of infiltration. AJNR Am J Neuroradiol 2005; 26: 706-10.
  12. Danelich IM, Wright SS, Lose JM, Tefft BJ, Cicci JD, Reed BN. Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease. Pharmacotherapy 2015; 35: 520-35. https://doi.org/10.1002/phar.1584
  13. Handin RI. The history of antithrombotic therapy: the discovery of heparin, the vitamin K antagonists, and the utility of aspirin. Hematol Oncol Clin North Am 2016; 30: 987-93. https://doi.org/10.1016/j.hoc.2016.06.002
  14. Smith DK, Demetriou T, Weber C. Aspirin for primary prevention: USPSTF recommendations for CVD and colorectal cancer. J Fam Pract 2019; 68: 146-51.
  15. MacKintosh ML, Crosbie EJ. Prevention strategies in endometrial carcinoma. Curr Oncol Rep 2018; 20: 101. https://doi.org/10.1007/s11912-018-0747-1
  16. Serrano D, Bonanni B, Brown K. Therapeutic cancer prevention: achievements and ongoing challenges - a focus on breast and colorectal cancer. Mol Oncol 2019; 13: 579-90. https://doi.org/10.1002/1878-0261.12461
  17. Hurwitz LM, Joshu CE, Barber JR, Prizment AE, Vitolins MZ, Jones MR, et al. Aspirin and non-aspirin NSAID use and prostate cancer incidence, mortality, and case fatality in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev 2019; 28: 563-9. https://doi.org/10.1158/1055-9965.EPI-18-0965
  18. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110: 255-8. https://doi.org/10.1016/S0049-3848(03)00379-7
  19. Botting RM. Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. Pharmacol Rep 2010; 62: 518-25. https://doi.org/10.1016/s1734-1140(10)70308-x
  20. Tosco P, Lazzarato L. Mechanistic insights into cyclooxygenase irreversible inactivation by aspirin. ChemMedChem 2009; 4: 939-45. https://doi.org/10.1002/cmdc.200800438
  21. Lucido MJ, Orlando BJ, Vecchio AJ, Malkowski MG. Crystal structure of aspirin-acetylated human cyclooxygenase-2: insight into the formation of products with reversed stereochemistry. Biochemistry 2016; 55: 1226-38. https://doi.org/10.1021/acs.biochem.5b01378
  22. Chiang N, Serhan CN. Aspirin triggers formation of antiinflammatory mediators: new mechanism for an old drug. Discov Med 2004; 4: 470-5.
  23. Brune K, Renner B, Tiegs G. Acetaminophen/paracetamol: a history of errors, failures and false decisions. Eur J Pain 2015; 19: 953-65. https://doi.org/10.1002/ejp.621
  24. Graham GG, Davies MJ, Day RO, Mohamudally A, Scott KF. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology 2013; 21: 201-32. https://doi.org/10.1007/s10787-013-0172-x
  25. Candido KD, Perozo OJ, Knezevic NN. Pharmacology of acetaminophen, nonsteroidal antiinflammatory drugs, and steroid medications: implications for anesthesia or unique associated risks. Anesthesiol Clin 2017; 35: e145-62. https://doi.org/10.1016/j.anclin.2017.01.020
  26. Schildknecht S, Daiber A, Ghisla S, Cohen RA, Bachschmid MM. Acetaminophen inhibits prostanoid synthesis by scavenging the PGHS-activator peroxynitrite. FASEB J 2008; 22: 215-24. https://doi.org/10.1096/fj.06-8015com
  27. Aminoshariae A, Khan A. Acetaminophen: old drug, new issues. J Endod 2015; 41: 588-93. https://doi.org/10.1016/j.joen.2015.01.024
  28. Smith HS. Potential analgesic mechanisms of acetaminophen. Pain Physician 2009; 12: 269-80. https://doi.org/10.36076/ppj.2009/12/269
  29. Sasaki F, Yokomizo T. The leukotriene receptors as therapeutic targets of inflammatory diseases. Int Immunol 2019; 31: 607-15. https://doi.org/10.1093/intimm/dxz044
  30. Vyvey M. Steroids as pain relief adjuvants. Can Fam Physician 2010; 56: 1295-7.
  31. Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 123-34. https://doi.org/10.1016/S0952-3278(03)00073-5
  32. Pathan H, Williams J. Basic opioid pharmacology: an update. Br J Pain 2012; 6: 11-6. https://doi.org/10.1177/2049463712438493
  33. Kreek MJ, Borg L, Ducat E, Ray B. Pharmacotherapy in the treatment of addiction: methadone. J Addict Dis 2010; 29: 200-16. https://doi.org/10.1080/10550881003684798
  34. Ok HG, Kim SY, Lee SJ, Kim TK, Huh BK, Kim KH. Can oliceridine (TRV130), an ideal novel ${\mu}$ receptor G protein pathway selective (${\mu}$-GPS) modulator, provide analgesia without opioid-related adverse reactions? Korean J Pain 2018; 31: 73-9. https://doi.org/10.3344/kjp.2018.31.2.73
  35. Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. Lancet Neurol 2014; 13: 924-35. https://doi.org/10.1016/s1474-4422(14)70102-4
  36. Bennett MI, Attal N, Backonja MM, Baron R, Bouhassira D, Freynhagen R, et al. Using screening tools to identify neuropathic pain. Pain 2007; 127: 199-203. https://doi.org/10.1016/j.pain.2006.10.034
  37. Cruccu G, Truini A. Tools for assessing neuropathic pain. PLoS Med 2009; 6: e1000045. https://doi.org/10.1371/journal.pmed.1000045
  38. Krause SJ, Backonja MM. Development of a neuropathic pain questionnaire. Clin J Pain 2003; 19: 306-14. https://doi.org/10.1097/00002508-200309000-00004
  39. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005; 114: 29-36. https://doi.org/10.1016/j.pain.2004.12.010
  40. Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain 2001; 92: 147-57. https://doi.org/10.1016/S0304-3959(00)00482-6
  41. Portenoy R. Development and testing of a neuropathic pain screening questionnaire: ID Pain. Curr Med Res Opin 2006; 22: 1555-65. https://doi.org/10.1185/030079906X115702
  42. Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006; 22: 1911-20. https://doi.org/10.1185/030079906x132488
  43. Obermann M. Treatment options in trigeminal neuralgia. Ther Adv Neurol Disord 2010; 3: 107-15. https://doi.org/10.1177/1756285609359317
  44. Di Stefano G, Truini A, Cruccu G. Current and innovative pharmacological options to treat typical and atypical trigeminal neuralgia. Drugs 2018; 78: 1433-42. https://doi.org/10.1007/s40265-018-0964-9
  45. Montano N, Conforti G, Di Bonaventura R, Meglio M, Fernandez E, Papacci F. Advances in diagnosis and treatment of trigeminal neuralgia. Ther Clin Risk Manag 2015; 11: 289-99. https://doi.org/10.2147/TCRM.S37592
  46. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1: 9-160. https://doi.org/10.1111/j.1468-2982.2003.00824.x
  47. Fricke-Galindo I, LLerena A, Jung-Cook H, Lopez-Lopez M. Carbamazepine adverse drug reactions. Expert Rev Clin Pharmacol 2018; 11: 705-18. https://doi.org/10.1080/17512433.2018.1486707
  48. Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 2004; 5: 627-35. https://doi.org/10.1016/j.yebeh.2004.07.004
  49. Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev 2017; 12: CD007963.
  50. Senderovich H, Jeyapragasan G. Is there a role for combined use of gabapentin and pregabalin in pain control? Too good to be true? Curr Med Res Opin 2018; 34: 677-82. https://doi.org/10.1080/03007995.2017.1391756
  51. Kim ES, Deeks ED. Gabapentin enacarbil: a review in restless legs syndrome. Drugs 2016; 76: 879-87. https://doi.org/10.1007/s40265-016-0584-1
  52. Yang JY, Lee WI, Shin WK, Kim CH, Baik SW, Kim KH. Administration of four different doses of gabapentin reduces awakening from breakthrough pain and adverse effects in outpatients with neuropathic pain during the initial titration. Korean J Anesthesiol 2013; 65: 48-54. https://doi.org/10.4097/kjae.2013.65.1.48
  53. Serpell M, Latymer M, Almas M, Ortiz M, Parsons B, Prieto R. Neuropathic pain responds better to increased doses of pregabalin: an in-depth analysis of flexible-dose clinical trials. J Pain Res 2017; 10: 1769-76. https://doi.org/10.2147/JPR.S129832
  54. Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, et al. Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the ${\alpha}2{\delta}$ subunit of voltage-gated calcium channels. J Pharmacol Exp Ther 2018; 365: 573-82. https://doi.org/10.1124/jpet.117.247551
  55. Javed S, Alam U, Malik RA. Mirogabalin and emerging therapies for diabetic neuropathy. J Pain Res 2018; 11: 1559-66. https://doi.org/10.2147/JPR.S145999
  56. Kim KH, Abdi S. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain 2014; 27: 103-11. https://doi.org/10.3344/kjp.2014.27.2.103
  57. Max MB, Gilron IH. Antidepressants, muscle relaxants, and N-methyl-D-aspartate receptor antagonists. In: Bonica's management of pain. 3rd ed. Edited by Loeser JD. Philadelphia (PA), Lippincott Williams & Wilkins. 2000, pp 1710-26.
  58. Choi YM, Kim KH. Etifoxine for pain patients with anxiety. Korean J Pain 2015; 28: 4-10. https://doi.org/10.3344/kjp.2015.28.1.4
  59. Shin SW, Lee JS, Abdi S, Lee SJ, Kim KH. Antipsychotics for patients with pain. Korean J Pain 2019; 32: 3-11. https://doi.org/10.3344/kjp.2018.32.1.3

피인용 문헌

  1. Mirogabalin: could it be the next generation gabapentin or pregabalin? vol.34, pp.1, 2020, https://doi.org/10.3344/kjp.2021.34.1.4
  2. Opioids and cancer prognosis: A summary of the clinical evidence vol.746, 2020, https://doi.org/10.1016/j.neulet.2021.135661
  3. The why behind the high: determinants of neurocognition during acute cannabis exposure vol.22, pp.7, 2020, https://doi.org/10.1038/s41583-021-00466-4
  4. Efficacy and Safety Considerations With Second-Generation Antipsychotics as Adjunctive Analgesics: A Review of Literature vol.37, pp.4, 2020, https://doi.org/10.1177/87551225211004145
  5. Design of Mucoadhesive Strips for Buccal Fast Release of Tramadol vol.13, pp.8, 2020, https://doi.org/10.3390/pharmaceutics13081187
  6. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review vol.13, pp.3, 2020, https://doi.org/10.3390/neurolint13030038
  7. Mechanisms, Diagnosis, and Medical Management of Hyperalgesia: an Educational Review vol.11, pp.4, 2020, https://doi.org/10.1007/s40140-021-00485-y
  8. Timing of musculoskeletal steroid injections in pain practice during Coronavirus disease 2019 (COVID-19) vaccine administration vol.35, pp.1, 2020, https://doi.org/10.3344/kjp.2022.35.1.1